A new publication involving anamorelin was released on August 1, 2026. The study, titled "A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA)," appeared in the Journal of Cachexia, Sarcopenia and Muscle.
The publication is described as a prospective observational study examining anamorelin use during chemoimmunotherapy in patients with non-small cell lung cancer who have cachexia. Anamorelin remains classified as an unapproved research compound.
No findings, outcomes, or safety data from this study have been provided at this time. This brief reports only the existence and identification details of the publication as listed in the source record, including its title, journal, and publication date.
Readers interested in this compound can consult the compound overview for additional background and context on anamorelin's research status.